tildrakizumab

Ligand id: 8093

Name: tildrakizumab

Immunopharmacology Comments
Tildrakizumab inhibits IL-23 receptor signalling by sequestering free ligand. This action down modulates the release of pro-inflammatory cytokines and chemokines, and reduces disease pathology.
Immunopharmacology Disease
Disease X-Refs Comment References
Psoriasis Disease Ontology: DOID:8893
Approved drug for moderate to severe plaque psoriasis. 3